Index

A
Aberrant crypt foci (ACF), 292
Acetogenins (ACGs), 293
Age-related bone loss
  childhood and adolescence, 122
  osteoporosis prevention, 123
  premenopausal women, 129
Alpha-linolenic acid (ALA), 291
Alpha-lipoic acid (ALA), 444
_Amaranthus viridis_ (Linn), 266–267
American Association of Diabetes Educators (AADE), 395
American Chamber of Commerce Researchers Association (ACCRA), 66
American Diabetes Association (ADA), 409
Angiotensin-converting enzyme inhibitors (ACEI), 305
Angiotensin-II (ANG-II), 305
Anthocyanins, 169
Anti-aging
  benefit, 232
  cardiovascular health, 241
  cosmetic and plastic surgery, 233–234
diets
  berries, 244
  biochemical reactions, 245–246
  calorie restriction, 243–244
cereals, 244
daily eat, 245
drink water, 244
  healthy avocados and watermelon, 244
  nuts, 245
  vegetables, 244–245
exercise, 247–248
  facial aesthetic industry, 232
fat transfers, 233
flexibility, 241
health products, 248
lifestyle changes, 242–243
minimally invasive procedures, 234–235
muscular strength, 241
natural solutions, 242
non-invasive treatment
  fraxel laser treatment, 239–240
  intense pulsed light, 238
  plasma skin resurfacing, 239
  thermage, 239
research, 249
  skin care, 232
  stem cell treatments, 233
Antioxidant activity, 180–181
Antioxidant phytochemicals, 171
Antiviral potential, vegetables
  antiviral properties, 265–270
categorized, 260
disease management, 272–273
food culture, 260
health benefits, 260–261
human daily diets, 273
medicinal properties, 270–272
nutrients, 261–265
Apigenin, 179
_Arcobacter butzleri_, 279
_Arcobacter cryaerophilus_, 279
Ascorbic acid, 174–175
_Astaxanthin_, 172

B
Beta-blocker therapy, 361
Biofortification, 203–204
Biological aging
  melanocytes, 231–232
  skin aging, 230–231
Body mass index (BMI), 366
Bone health
  bone development, 122–123
  nutritional interventions
    childhood, 123–129
    cost-effectiveness, 133–135
    premenopausal women, 129–133
Botulinum toxin (BOTOX), 234
Browning effects, 228
Caffeic acid, 181
Calorie restriction, 243–244
Carcinogens, 180
Cardiovascular disease (CVD), 323, 366, 405, 428, 467
Carotenoids, 171–172
Catechin, 170
CDL. See Chronic diseases of lifestyle
Ceratotheca sesamoides (Endl) definition, 269
nutritional composition, 270
CHD. See Coronary heart disease
Chemical peels, 235
Chemopreventive effects antioxidant and anticancer properties, 298
phytochemicals, cancer chemoprevention annatto, 288
avocado, 289–290
aztec spinach, 290
beans, 290–291
black sapote, 291
chia, 291
chickpea, 292
chili peppers, 292–293
christophene, 293
custard apple, 293
ground cherry, 294
guava, 294
mamey sapota, 295
mammee apple, 294
papaya, 295
roselle, 295
sapodilla, 296
soursop, 296
sweet potato, 296
sweeptop, 296–297
tree spinach, 297
white sapote, 297–298
Child morbidity, 191
Chronic diseases fruit and vegetable consumption, 106
noncommunicable diseases, 367–368
program effects, 113
Chronic diseases of lifestyle (CDL), 19
Chronic kidney disease aging, 305
bioactive dietary supplements cost benefits, 310–311
standardize measurement, 309
uses, 311
cardiovascular disease, 302
classification, 303
dietary antioxidant, 309
drugs, 305
morphological changes, 303, 304
obesity, 303–304
RAAS injury, 302
renal fibrosis, 303
screening and treatment strategies, 302
smoking, 305
treatment anti-inflammatory effects, 308–309
antioxidants, 307–308
glucose modulation, 306
lipid modulation, 306–307
renin-angiotensin-aldosterone system, 305–306
Citrus products animal feeding antioxidant activity, 280
orange peel/dried orange pulp, 280–282
swine, 281
antibacterial/antimicrobial activities, 277, 282
foodborne pathogenic bacteria and citrus oils, 279–280
natural antimicrobial essential oils, 278–279
primary fractions, 278
pathogenic bacteria, 277
CNPP food prices database, 45
Conjugated linoleic acid (CLA), 289
Continuing survey of food intakes among individuals (CSFII), 65–66
Coronary heart disease (CHD), 21, 323, 367
Cosmetic vs. natural treatments aging
biological/intrinsic aging, 228, 230–232
browning effects, 228
environmental aging, 228–229
facial rejuvenation techniques costs, 240–241
genetic factors, 228
mechanical aging, 229
physiology, 229–230
symptoms, 228
anti-aging benefit, 232
cardiovascular health, 241
cosmetic and plastic surgery, 233–234
exercise, 247–248
facial aesthetic industry, 232
fat transfers, 233
flexibility, 241
health products, 248
lifestyle changes, 242–243
minimally invasive procedures, 234–235
muscular strength, 241
natural solutions, 242
non-invasive, 238–240
research, 249
skin care, 232
stem cell treatments, 233
botulinum toxin, 237–238
dermal fillers (see Dermal fillers)
Cost benefit analysis, 34
Cost effective natural antioxidants. See Natural antioxidants
Cost effectiveness cost-minimization analysis, 153
dental caries prevention, 149–151
fortified food methodology, 33–34
glycemic control
cost savings, 400
DPP, 398
economic impact, 392
health care expenditures, 392
health economic benefits, 399
lifestyle interventions, 398, 399
lifestyle modifications, 394–397
pharmacoeconomic principles, 392–394
prospective and a retrospective study, 397
UKPDS, 398
medicine, 20–21
nutrition policy, 14
type II diabetes, 462
Cost-minimization analysis
cost-effectiveness ratio, 156–157
costs, 153
effectiveness, 153–154
C-reactive protein (CRP), 339
CVD. See Cardiovascular disease

D
DALY. See Disability adjusted life years
Dental caries
cost-effectiveness, 149–151
cost saving, 150
scheme characteristics, 148
Dermal fillers
collagen based, 236–237
permanent/nonresorbable, 236
skin problems, 237
Diabetes
achieve and maintain, 440–441
alcohol, 443
autoimmune diseases, 426
bariatric surgery, 446
barriers, 445
biological mediator, 458
carbohydrates, 442
cardiovascular and noncommunicable diseases
antioxidant activity, 375
chronic diseases, 367–368
cost, 370–371
deliberate interventions, 385
diet, 369
dietary components, 375
dietary supplements and nutriceuticals, 377
 genetic components, 377–378
 genetics and nutrigenomics, 384
 indolic polyphenols, 375
 macronutrients, 373–374
 mediterranean diet, 376–377
 micronutrients, 374
 nutrient intake goals, 372
 nutrition interventions, 383–384
obesity, 365–366
public health, 378–383
risk factors, 369–370
sodium chloride, 370
vegetarian diets, 376
causes, 427
chronic illness, 425–426
classification, 426
complications, 458
cows milk, 444
diabetes prevention and MNT (medical nutrition therapy), 440–441
diagnosis
asymptotic patients, 429
hyperglycemia, 428
type I diabetes, 429
type II diabetes, 429
dietary fat, 443
dietary supplements, 444–445
effectiveness of MNT, 441–442
estimated indirect costs, 431–432
gestational diabetes, 427
lifestyle changes vs. metformin DPP, 437
ethical implications, 439–440
non-medical costs, 437–438
placebo intervention, 438
QALY, 438–439
medical costs, 436–437
medical expenditures, 431
medical nutrition therapy, 440
metformin treatment, 463
micronutrients, 443
microvascular disease, 460
multiple lifestyle changes, 446
obesity, 448
pharmaceutical therapy, 463
pharmacological treatment, 446
physical activity, 448
prevalence, 458
pycnogenol supplementation
cardiovascular disease, 459–460
HbA1c levels, 458–459
race and ethnic differences, 430–431
risk factors and complications, 427–428
self-management education, 446
type I diabetes, 426
type II diabetes
cost-effectiveness, 462
glycemic control, 461
goals and behavior, 435
LDL levels, 462–463
lifestyle interventions, 434–435
physical activity treatment plans, 435–436
primary prevention, 433–434
weight loss, 447
whole grains and fiber, 443
Diabetes Prevention Program (DPP), 395, 437
Diabetes self management education (DSME), 396, 449
Diastolic blood pressure (DBP), 326, 339
Dietary intake and income vs. fruit and vegetable price
  ACCRA data, 66
  continuing survey of food intakes among individuals (CSFII), 65–66
  food price effects, 68–69
  household consumption, 69–70
  National Longitudinal Survey of Youth 1997 (NLSY97), 66
  National Rural Household Survey, 70
  price elasticity, 67
Dietary patterns
  factors, 79
  fruit and vegetable consumption, 80
  obesity and lifestyles, 79
  take-out food, 79
Dietary polyphenols, 181
Dietary reference intake (DRI), 443
Dietary salt reduction, 21–22
Dietary supplements
  CNPP food prices database, 45
  diabetes, 444–445
  DSID, 44
  economic value, 41–42
  food data comes, 44
  group A nutrition policy, 22
  least-cost diet approach
    CNPP food prices database, 45
    computer recommendation, 46
    updated prices, 47–49
  linear programming, 42
  MCDP model, 43
  National Health and Nutrition Examination Survey, 45
  nutritional requirements, 43–44
Dietary supplements ingredient database
  (DSID), 44
  1, 2-Dimethylhydrazine (DMH), 288
Disability adjusted life years (DALY), 192, 340

E
Economic incentive instruments
  design and magnitude, 9–11
  external effects, 4
  food taxes/subsidies, 4
  incentive schemes, 11–16
  principles, 4–5
  targeting, 5–9
Ellagic acid, 169
Endothelial function, 469–470
End stage kidney disease (ESKD), 301
Environmental aging, 228–229
Escherichia coli O157:H7, 281
Estrogen receptor (ER), 289
Ethnic identity, 76
Ethnicity
  behavioral intentions, 83
  children and relations, 80–81
  cultural dimensions, 76
  dietary patterns and health implications, 78–80
  empirical studies, 83
  food preparation and consumption, 76
  personal and social identity, 76
  social, medical, and economic implications, 76
  vs. food choice
    acculturation factor, 77
    dietary choices, 77
    energy and macronutrient intake patterns, 77
    food consumption, 78
    social and cognitive psychology, 82–83
    three-dimensional model, 78
Euphorbia lateriflora (Schum and Thonn), 267

F
Fasting plasma glucose (FPG), 428
Flavanol-free white chocolate (FFWC), 333
Flavanol-rich dark (FRDC), 333
Fluoridation. See Milk fluoridation
Folic acid deficiency, 35–36
Food advertising, 24
Food and agriculture office (FAO), 405
Food choice
  acculturation factor and dietary choices, 77
  food consumption, 78
  macronutrient intake patterns and energy, 77
  social and cognitive psychology, 82–83
  three-dimensional model, 78
Food consumption
  children and adolescents, 81
  social groups and categories, 80
Food fortification
  economic benefits, 32
  flour, 37
  fortified complementary foods, 38–39
  home fortification, 38
  mandatory vs. voluntary, 33
  market-driven, 33
  mass, 32
  micronutrient deficiencies
    calcium, 36
    folic acid, 35–36
    iodine, 35
    iron, 34–35
    selenium, 36
    vitamin A, 34–35
    vitamin D, 36
    zinc, 36
  multiple micronutrient powders, 38
  salt, 37
  soy sauce and fish sauce, 37
  targeted, 32–33
  zinc fortification, 202–203
Food labels, 23–24
Food prices, 25–26
Food stamp program, 111
Fortification
food fortification (see Food fortification), 39
micronutrient, 39
milk fluoridation (see Milk fluoridation), 239–240
Fraxel laser treatment, 239–240
Fruit and vegetable (FV) consumption
chronic disease, 106
commodities analysis, 109, 110
consumption data, 110–111
data analysis strategy, 108–109
economic incentives, 107
elasticities, 111
expenditures, 106
health benefits, 106
log-linear specification, 116–118
low socioeconomic status, 106
market demand equations, 114
marketing sector, 115
market supply equations, 114–115
net benefits, 113
price subsidy, 107–108
production and trade, 111
public subsidy cost, 112–113
simulations, 109
SNAP beneficiaries, 111–112
Supplemental Nutrition Assistance Program, 106
food shopping, 59
influence model, 58
key variables, 59–60
model test, 60
nutritional interventions, childhood, 128
price
economic model, 63–64
five-a-day campaign, 63
food cost, 64
USDA’s recommendations, 63
vs. dietary intake and income, 65–70
qualitative research, 58

G
Gastrointestinal cancer (GC), 290
Glomerular filtration rate (GFR), 303
Glycemic control
cost savings, 400
DPP, 398
economic impact, 392
health care expenditures, 392
health economic benefits, 399
lifestyle interventions, 398, 399
lifestyle modifications, 394–397
pharmacoeconomic principles, 392–394
prospective and a retrospective study, 397
UKPDS, 398
Glycemic index (GI)
benefits, 410
children and adolescent, 412
complex carbohydrates, 406
evaluation, 406–407
factors, 420–421
glycemic load, 409–410
healthy combinations, 408
high-fat products, 409
hydrogenated oils, 416
insulin, 408–409
jigsaw, 409
non-diabetic, 410
nutrition therapy, 405
obese adults, 404
prevalence, 403–404
ratings, 409
weight loss, 411–412
Government policy, 23
Gross domestic product (GDP), 361

H
HDL-atherosclerosis treatment study (HATS), 338
Health care, 19, 27
Healthcare Cost and Utilization Project (HCUP), 394
Health promotion, 23
Helicobacter pylori, 279
High-density lipoprotein (HDL), 303
Home fortification, 38
Hyaluronic acid (dermal filler), 235
Hydrogenated oils, 23
Hypertension
BP management, 324
carbohydrate, 330
chocolate intake
cocoa, 332–333
FRDC, 333–334
cost vs. benefit
β-blockers, 341
blood pressure (BP), 340–341
nutritional management, 341
dietary approach to stop hypertension (DASH) diet, 327–328
dietary factors
alcohol drinking pattern, 331–332
epidemiology, 331
moderation in alcohol intake, 330–331
dietary fiber supplementation, 350
dietary potassium, 326–327
dietary salt (sodium) reduction, 325–326
fruit and vegetable, 330
life expectancy, 324
mediterranean diet, 328
nutritional supplementation
calcium, 336–337
fish and fish oils, 339
magnesium, 337–338
multivitamins and minerals, 339
selenium, 338–33
vegetarian, 328–329
vitamin B and folate, 334
vitamin C, 335
vitamin D, 336
vitamin E, 334
Hypertension (cont.)
recommendations, 327
and related effects, 324
sodium and potassium, 324–325
vegetarian, 328–329
weight loss, 340
weight management, 339

I
Impaired fasting glucose (IFG), 428
Impaired glucose tolerance (IGT), 428
Indian Health Service (IHS), 430
Intermediate hyperglycemia (IHG), 369
Intrinsic aging. See Biological aging
Iodine deficiency, 35
Ischemic heart diseases (IHD), 376
Item response modeling (IRM), 59–60

L
Lactose and lactase deficiency, 94
Lactuca taraxacifolia (Wild), 267–269
Laser hair removal, 235
Least-cost diet approach
  CNPP food prices database, 45
  computer recommendation, 46
  updated prices, 47–49
Lifestyle modification
  DSME and AADE 7 self-care behaviors, 396
  efficacy and safety, 397
  mechanism, 395
  medical nutrition therapy, 395, 396
  oral hypoglycemic therapy, 396
  resistance training and aerobics, 396
Linear program (LP), 42
Lipoic acids, 175–176
Low-density lipoprotein (LDL), 303

M
Macronutrients, 373–374
Malnutrition
  inequality levels, 91–92
  lactose and lactase deficiency, 94
  mortality, 92
  nutricam
    cost of, 97
    nutritional education and failure, 102
    nutritional rehabilitation, 100, 103
    outcome variables, 100, 102
    project implementation, 102
    weight gain analysis, 98, 99
  precaution, 103
  programs and support, 92–93
  supplementary feeds, 95–96
  treatment, 94–95
  UNICEF, 93–94
  WHO, 93–94
Market-driven fortification, 33
Markov model, 354, 356
Mass fortification, 32
MCDP model, 43
Mechanical aging, 229
Medical nutrition therapy (MNT), 395
Mediterranean diet
  analysis, 355
  beta-blocker therapy, 361
  cost, 352–354
  economic evaluation, 358
  economic performance, 352
  effectiveness, 351
  heart disease, 349
  incremental cost, 352
  intervention, 350–351
  modeling, 354–355
  myocardial infarction, 350
  noncommunicable diseases, 376–377
  perspective, 350
  sensitivity analyses, 356–358
  strengths and limitations, 360–361
Micro dermabrasion, 235
Micronutrient deficiency
  calcium, 36
  folic acid, 35–36
  iodine, 35
  iron, 34–35
  selenium, 36
  vitamin A, 34–35
  vitamin D, 36
  zinc, 36
Milk fluoridation
  advantages and limitation, 146
  attributes, 145
  clinical studies, 146
  cost-minimization analysis
    cost-effectiveness ratio, 156–157
    costs, 153
    effectiveness, 153–154
  dental caries prevention
    cost-effectiveness, 149–151
    cost-effectiveness ratio, 150–151
    cost saving, 150
    scheme characteristics, 148
  fluoride addition, 146–147
  mechanisms, 145
  in rural areas, 151–152
Monosaturated fatty acids (MUFA), 369
Multivitamin and mineral supplementation (MMS), 339

N
N-acetyl-cysteine (NAC), 308
National Health and Nutrition Examination Survey (NHANES), 45
National Longitudinal Survey of Youth 1997 (NLSY97), 66
National Rural Household Survey (NRHS), 70
Natural antioxidants
  animal sources, 171
antioxidant activity, 180–181
antioxidant phytochemicals, 171
ascorbic acid, 174–175
beverages, medicinal plants and spices, 170
carotenoids, 171–172
cereals and legumes, 170
dietary polyphenols, 181
fruits, 169
lipoic acids, 175–176
natural dietary sources of polyphenols, 166
neutralizing antioxidant, 164
oilseeds, 167–169
polyphenolic contents, 167
polyphenols
anthocyanins and proanthocyanidins, 178
carcinoids, 177
classification, 176
ellagic acid, 176, 177
flavones and flavonoids, 177
hydroxyl groups, 179
isoflavones, 180
phenolic acids, 176
reactive oxygen species, 164
vegetables, 165, 167
vitamin E (tocopherols and tocotrienols), 173–174
Nifedipine, 472
Nutricam
cost of, 97
nutritional education and failure, 102
nutritional rehabilitation, 100, 103
outcome variables, 100, 102
project implementation, 102
weight gain analysis, 98, 99
Nutritional interventions
childhood
breastfeeding, 125–126
calcium, 126
cost-effectiveness, 133–135
fruit and vegetables, 128
maternal diet, 124–125
peak bone mass, 122
salt, 128–129
soft drinks and milk avoidance, 129
vitamin D, 126–128
premenopausal women
calcium, 130–131
vitamin D, 132–133
Nutrition policy
economic incentive instruments
behavioral parameters, 11
cost-effectiveness, 14
decision environment, 6
dietary behavior, 10
discrete approach, 9
distortionary costs, 8
economic considerations, 6, 15
economic externality, 4, 5
economic regulation, 8
effectiveness of regulation, 7
feasibility, 9
food consumption behavior, 15
free-riding behavior, 10
future liability, 13
individuals’ nutritional decisions, 6
market prices, 10
model assumptions, 11
net economic welfare effects, 13
policy intervention and measure, 7
poor diet, 14
positive externalities, 5
progressive incentive scheme, 9
short-term and long-term effects, 15
tax effects and transaction costs, 8
group A
dietary salt reduction, 21–22
dietary supplements, 22
food labels, 23–24
health promotion, 23
trans fatty acids, 22–23
group B
children and adolescents, 24–25
food prices, 25–26
medicine cost-effectiveness, 20–21
public health, 21
O
Obesity
chronic kidney disease, 303–304
diabetes
adult deaths, 405
advanced carbohydrate counting, 413–414
advanced level, 413–414
basic carbohydrates, 408
benefits, 410
blood sugar, 416–417
blood sugar levels, 407
calorie counting and fat counting, 414
calories, 417–418
carbohydrate counting, 413
children and adolescent, 412
combined approach, 406
evaluation, 406–407
exchange list, 413
factors, 420–421
fullness factor, low-carb diets, 419
GI and GL values, 415
glycemic load, 409–410
healthy combinations, 408
individualized menus, 412
insulin, 408–409
jigsaw, 409
low GI foods, 414
meals 1-5, 413
non-diabetic, 410
nutrition therapy, 405
obese adults, 404
Obesity
diabetes (cont.)
prevalence, 403–404
ratings, 409
satiety index values, 418
weight loss, 411–412
work, 419
roselle, 221

ODC. See Ornithine decarboxylase
OGTT. See Oral glucose tolerance test
Omega-3 fatty acids, 444–445
Oral glucose tolerance test (OGTT), 428
Oral health, 143
Ornithine decarboxylase (ODC), 297
Oryzanol, 167

Osteoporosis
calcium supplementation, 126
economic evaluation, 133
implication and prevention, 122–123
nutritional intervention, men and women, 132–133
peak bone mass, 134

Oxygen radical absorbance capacity (ORAC), 261, 309, 469

Pantothenic acid (B5), 263
Peak bone mass, 134

Phytochemicals, cancer chemoprevention
annatto, 288
avocado, 289–290
aztec spinach, 290
beans, 290–291
black sapote and chía, 291
chickpea, 292
chili peppers, 292–293
christophene and custard apple, 293
ground cherry, 294
guava, 294
mamey sapota, 295
mammee apple, 294
papaya and roselle, 295
sweet potato, sapodilla and soursop, 296
sweetsop, 296–297
tree spinach, 297
white sapote, 297–298

Platelet aggregation, 470

Polyphenols
anthocyanins and proanthocyanidins, 178
chalcones, 177
classification, 176
ellagic acid, 176, 177
flavones and flavonoids, 177
hydroxy groups, 179
isoflavones, 180
phenolic acids, 176

Polyunsaturated fatty acids (PUFA), 369

Preoperative immunonutrition
cancer patients, 316–317
cost-benefit analysis
DRG reimbursement, 319
infectious and non-infectious complications, 318
GI cancer, 316
gram-positive and gram-negative, 315
post-hoc analysis and prolonging infusion, 317

Price, fruit and vegetable
subsidy
economic effects, 106
net benefits, 113
public cost, 109
SNAP beneficiaries, 114
vs. dietary intake and income (see Dietary intake and income vs. fruit and vegetable price)

Public health, 21
global food policy, 382
individual behavior, 379–380
infants and young children, 382
obesity, 379
obesogenic environment, 380
physical activity, 382–383

PUFA. See Polyunsaturated fatty acids

Pycnogenol supplementation
biological profile, 468
cardiovascular disease, 459–460
cost and benefits, 463
cost benefit analysis
ACE inhibitors, 470
cholesterol levels, 471
nifedipine, 472
platelet aggregation, 472–473
HbA1c levels, 458–459
pharmaceutical drug treatments, 473
risk factors
diabetes, 469
dyslipidemia, 469
endothelial function, 469–470
hypertension, 468–469
platelet aggregation, 470
type II diabetes
cost-effectiveness, 462
glycemic control, 461
LDL levels, 462–463

Pyridoxine (B6), 263

Quality adjusted life year (QALY), 20, 350, 438

Quercetin, 179

Reactive oxygen species (ROS), 164, 289
Renin-angiotensin-aldosterone system (RAAS), 302
Riboflavin (B2), 263
Ribosome-inactivating protein (RIP), 293
ROS. See Reactive oxygen species
Roselle (Hibiscus sabdariffa)
Index

antihypertensive and antilipidemic effects
angiotensin-converting enzyme, 219
low-density lipoprotein, 220
randomized controlled clinical trial, 221
Roselle anthocyanins, 219
Roselle calyx extract, 220
Roselle extract powder, 219
antioxidant effects, 217–218
chemopreventive effects against cancer, 221–222
hematological parameter effects, 217
hepatoprotective effects, 222–223
hypoglycemic effects, 218
Mexican traditional medicine, 216
radiation effects, 223
safety, 223–224
therapeutic value, 216
weight loss and obesity, 221

S
Salmonella, 281
Skin rejuvenation, 235
Socioeconomic status (SES), 67
Sterols, 167
Superoxide dismutase (SOD), 289
Supplemental Nutrition Assistance Program (SNAP), 114
Systolic blood pressure (SBP), 333, 339

T
Targeted fortification, 32–33
Terpenes, 171
12-O-Tetradecanoylphorbol 13-acetate (TPA), 297
Theory of planned behavior (TPB), 83
Thiamine (B1), 263
α Tocopherol, 308
Tocotrienols, 173–174
Trans fatty acids, 22–23
Transforming growth factor-beta (TGF-β), 304
Trials of hypertension prevention (TOHP), 325
Trolox equivalent antioxidant capacity (TEAC), 309
Type I diabetes, 429
Type II diabetes
economic cost, 392
mechanisms, 395
MNT and DSME, 396
precaution, 398
pycnogenol supplementation
cost-effectiveness, 462
glycemic control, 461
LDL levels, 462–463
Urolithiasis, 223
US Dietary Supplement Health and Education Act, 41

V
Vegetables
antiviral properties
A. viridis (Linn), 266–267
Ceratotheca sesamoides (Endl), 269–270
Euphorbia lateriflora (Schum and Thonn), 267
Lactuca taraxacifolia (Wild), 267–269
consumption
chronic disease, 106
economic incentives, 107
SNAP beneficiaries, 112
disease management, 272–273
health benefits, 260–261
medicinal properties
G. latifolium, 270–271
O. gratissimum (Scent Leaf), 270
P. guineense, 271–272
V. amygdalina (Bitter Leaf), 271
nutrients
fiber, 265
useful antioxidants, 261–262
vitamins and minerals, 263–265
Vegetarian diets, 376
Vitamin A, micronutrient deficiencies, 34–35
Vitamin D, 126–128

W
World Health Organization (WHO)
guidelines on food fortification with
micronutrients, 32
malnutrition, 93–94

Z
Zinc deficiency, 36, 191, 192
Zinc intervention strategies
deficiency, 190
dietary diversification and modification, 198–199
dietary zinc and risk of cancer, 199–201
dietary zinc definition, 190
nutrition and human health
child morbidity, 191
copenhagen consensus on hunger and
malnutrition, 194
micronutrient malnutrition, 192
risk of diarrhea, 191
single-micronutrient studies, 194
undernourishment, 192
zinc-fortification programs, 195
systematic review, 195
zinc fortification
biofortification, 203–204
food fortification, 202–203

United Kingdom Prospective Diabetes Study (UKPDS), 398
<table>
<thead>
<tr>
<th>Zinc intervention strategies</th>
<th>zinc supplementation</th>
</tr>
</thead>
<tbody>
<tr>
<td>zinc fortification (cont.)</td>
<td>advantage, 195</td>
</tr>
<tr>
<td>genetic and molecular technologies, 204</td>
<td>breastfeeding, 196</td>
</tr>
<tr>
<td>inadequate dietary intake, 201</td>
<td>child mortality, 196</td>
</tr>
<tr>
<td>limitations, 206</td>
<td>diarrhea, 196</td>
</tr>
<tr>
<td>multipronged approach, 202</td>
<td>health care</td>
</tr>
<tr>
<td>phytases, 205</td>
<td>delivery system, 197</td>
</tr>
<tr>
<td>zinc status assessment, 201</td>
<td>zinc sulfate tablets, 197</td>
</tr>
</tbody>
</table>